GlaxoSmithKline (GSK) confirmed that the European Commission (EC) has granted a conditional marketing authorisation for Votrient (pazopanib) for the first-line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. As part of these conditions, GSK will provide data from ongoing clinical studies.
The US Food and Drug Administration (FDA) approved the use of Votrient (pazopanib) as a treatment for patients with advanced RCC in October 2009.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.